Navigation Links
Cargill Executive Joins Blue Cross Board of Trustees
Date:11/3/2008

EAGAN, Minn., Nov. 3 /PRNewswire/ -- Blue Cross and Blue Shield of Minnesota (Blue Cross) has named Rita Heise, corporate vice president and chief information officer for Cargill, to its board of trustees. She will serve on the board's human resources and finance and business development committees.

At Cargill, Heise is responsible for information technology worldwide. She is a member of Cargill's corporate center, the business conduct committee and the Tartan leadership team.

Prior to joining Cargill, Heise was the chief information officer for Honeywell's Aerospace business and for Honeywell's Europe, Middle East, and Africa operations. She has worked on business integrations, process improvement teams and mergers/acquisitions throughout her career.

"I am very pleased to welcome Rita as Blue Cross' newest trustee," said Patrick Geraghty, president and CEO of Blue Cross. "She is an outstanding leader whose considerable business expertise will be of tremendous value to the work of our board."

Heise received bachelor's degrees in computer science and mathematics and has an MBA from St. Thomas University. She participates on IT industry committees, serves on the board of Adventium Labs and represents Cargill on advisory boards with Dell Corporation and the College of St. Catherine. Blue Cross operates under the guidance of the board which oversees the organization's work as a nonprofit health service plan corporation.

Blue Cross and Blue Shield of Minnesota, with headquarters in the St. Paul suburb of Eagan, was chartered in 1933 as Minnesota's first health plan and continues to carry out its charter mission today: to promote a wider, more economical and timely availability of health services for the people of Minnesota. A nonprofit, taxable organization, Blue Cross is the largest health plan based in Minnesota, covering 2.9 million members in Minnesota and nationally through its health plans or plans administered by its affil
'/>"/>

SOURCE Blue Cross and Blue Shield of Minnesota
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. E. Coli Registry Expanded for Victims of E. Coli Poisoning from Cargill Ground Beef
2. Volunteer for National Suicide Prevention Agency Earns Cargill Award
3. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
4. Align Technology Executive to Present at Upcoming Financial Conferences
5. Mediware Names Thomas K. Mann Chief Executive Officer
6. PRA International Adds Dr. Susan Stansfield as Executive Vice President
7. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
8. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Business Executives Discuss National Health Care Reform at Conference Sponsored by The Century Foundation, with Support from The Commonwealth Fund, and AARP
11. Response Biomedical appoints S. Wayne Kay Chief Executive Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)..., Nov. 9 Highlighting a commitment...th advanced entertainment and digital display tech...atest Long-Term Care and Hospital Grade LCD HDTVs ... for the Aging 2009 annual meeting and exposition ... new line of "HealthView(TM)" Long-Term Care LCD H...
(Date:11/9/2009)...K, Nov. 9 /PRNewswire/ -- Phoenix House , the...e treatment and prevention program, announced toda...lly and internationally recognized leader in subst...al Officer, effective January 1, 2010. ,, "Dr...e abuse treatment research and her work has result...
(Date:11/9/2009)...ents Support Experimental Procedure for Preteen So...swire/ -- For parents of children with cancer, the...e steadily improved for decades. Among the bad new...nfertility. ,, Boys diagnosed with cancer who...y to preserve their fertility: before undergoing c...
(Date:11/9/2009)...ildren,s Research Hospital and the University of F...aboration to provide proton therapy for St. Jude p...the first clinical study to evaluate the use of pr...unger than 3 years old. , Under the clinical p...roton therapy at the UF Proton Therapy Institute i...
(Date:11/9/2009)...10 million people around the world suffer from cat...Frankfurt and his coauthors discuss cataract surge...the current issue of Deutsches rzteblatt Internat...533;). , Blindness is usually due to opacificati...0 cataract operations are performed each year. Cat...
Breaking Medicine News(10 mins):Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 2Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 3Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 5Health News:Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research 2Health News:Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research 3Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 2Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 3Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 4Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2
...id arthritis (RA) face different treatment options...g . Two new studies examined patients decisions re...found that most RA patients are reluctant to chang...advances in RA treatment include multi-drug therap...
... Anthonys ability to walk. He and his mother feare...fined to a wheelchair. As is the case with...isorder, Anthony was left with few options and his...David M. Scher, M.D., a pediatric orthopedic surge...
...ted marketing authorization for INVEGA(TM) (palipe...ipsychotic medication for the treatment of schizo...y designed to deliver paliperidone - the active in... compared to placebo in helping many patients cont...
...ning have found that boys and girls are different ... However, they have suggested that this dissimil...ids from co-educational to segregated schools, or ...ching their teachers about the differences. ...
..."decrypting" an enzyme's function from its structu...e to drug discovery. Led by UCSF's Brian ...ge of Medicine, and Frank Raushel of Texas A and M... Shoichet says if the new strategy works with othe...
...n the last six years, death rates and heart failur...n sharply- most likely because of better treatmen...g trend parallels the growing use of cholesterol-l... professor at the University of Edinburgh: These r...
Other Medicine News:Health News:Alternative Treatments for Arthritis 2Health News:Alternative Treatments for Arthritis 3Health News:Motion Analysis Helps Teen With Cerebral Palsy Regain Ability to Walk 2Health News:Motion Analysis Helps Teen With Cerebral Palsy Regain Ability to Walk 3Health News:INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia 2Health News:INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia 3Health News:Boys and Girls are Different by Nature and Learn in Different Ways 2Health News:"Decryption" of Enzyme's Functions Paves Way for Future Drug Discovery 2Health News:Hearts Saved As Doctors Put Cutting Edge Discoveries to Use 2Health News:Hearts Saved As Doctors Put Cutting Edge Discoveries to Use 3
(Date:11/9/2009)...wire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT )...athologists, oncologists and the pharmaceutical in...ke presentations at two upcoming investor conferen... will be made at the Lazard Capital Markets Sixth ...sday, November 17. The conference will be held at ...
(Date:11/7/2009)...re/ -- Most patients with hereditary angioedema (H...g HAE attack giving the patients sufficient time t...sociated with that attack, according to survey fin... of Allergy, Asthma & Immunology (ACAAI) Annua...atigue and nausea, which occur frequently before a...
(Date:11/6/2009).... 6 In consultation with the U.S. ...r Healthcare, Division of McNEIL-PPC, Inc., is ini...product lots of TYLENOL® Arthritis Pain Caple...PEN CAP. McNeil is initiating the recall after ide...ated with these lots that led to a small number of...
Breaking Medicine Technology:Clarient to Present at Upcoming Healthcare Investor Conferences in New York City 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 3McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Ash Stevens Plans 246 Million Facility Expansion to Bolster CMC Capabilities 14293 1Ash Stevens Plans 246 Million Facility Expansion to Bolster CMC Capabilities 14293 2Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 1Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 2Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 4Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 5Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 6Have a Healthier Halloween with Tigers Milk 28R 29 58516 1Have a Healthier Halloween with Tigers Milk 28R 29 58516 2
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: